Key Drivers
- Cash cushion
- Ongoing losses
- No revenue
AIAI Summary
CMPS has shifted from a speculative science story to a late-stage, pre-commercial catalyst play with Phase III success, six-month durability, and a Q4 2026 NDA path that could support first revenue in 2027, but the investment still hinges on regulatory execution and DEA rescheduling rather than operating fundamentals, so any delay would materially reset the stock.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash cushion
- •Ongoing losses
- •No revenue
CMPS's balance sheet improved materially with cash now covering debt and equity positive, but it still has no revenue and continues to burn cash amid large losses. #burn-rate
Price Behavior
Key Price Behavior Insights:
- •Breakout momentum
- •Short-term extension
- •Support hold
CMPS remains constructive after breaking out from a late-July base over the last month, but it is short-term extended and must hold $13.18-$13.29 to keep the uptrend intact while $14.22 remains the key resistance.
Sharp rally from the late-July base to the 2026-08-12 peak, followed by a quick pullback
Sentiment & News
Key News Insights:
- •NDA On Track
- •VA Trial Expands
- •Prelaunch Hiring
Compass Pathways is advancing COMP360 toward a Q4 2026 NDA filing and potential H1 2027 U.S. launch, backed by positive Phase III data, a VA study expansion, and ongoing pre-commercial hiring.
The news is moderately positive for CMPS as it reinforces regulatory momentum and launch readiness, though execution risk remains until approval is secured
Similar Companies in Healthcare
Other companies in the same sector with AI ratings